Secretory Leucoprotease Inhibitor (SLPI)
Secretory Leucoprotease Inhibitor (SLPI) is a member of the Whey-Acidic Protein (WAP) family of proteins. These proteins share a conserved cysteine-rich four-disulphide core (FDC) domain and as the name suggests, these domains contain eight cysteine residues forming 4 disulphide bonds. SLPI contains two of FDC domains (1), and like many other FDC-containing proteins, is encoded on chromosome 20q12-13.2. Spanning approximately 2.6 kb, the SLPI gene consists of three introns and four exons (2, 3). SLPI is expressed in many locations but expression appears to be highest in lung and cervical mucosa, body fluids and skin (4).
The primary role of SLPI is as a serine protease inhibitor. It can protect tissue from degradation by a number of proteases such as Cathepsin G, elastase, trypsin, chymotrypsin, chymase and tryptase. However, Neutrophil Elastase (NE) is considered the principal protease target of SLPI (5); NE is produced by neutrophils and the excessive tissue damage evident in certain neutrophildominated diseases such as cystic fibrosis (CF) may be in part attributable to the action of this protease. The antiprotease activity of SLPI lies in the C-terminal domain, and in particular, the active site is located at the Leu 72 -Met 73 residues of domain 2 (6).
The high local concentration of SLPI in the upper airways and the fact that it has been shown to associate with elastin fibres in the lung (and skin) illustrate a key role for SLPI in protecting the local lung tissue from neutrophil-derived serine proteases (7). In a high protease milieu SLPI is itself cleaved by endogenous proteases, such as the cysteinyl cathepsins (8), NE itself (9), but also by proteases derived from pathogens such as Pseudomonas aeruginosa (10). Furthermore oxidation of the Met 73 residue has been shown reduce the inhibitory potential of SLPI, and the increased intrapulmonary oxidative stress and pathogenic bioburden in patients with neutrophil-dominated lung diseases such as chronic obstructive pulmonary disease (COPD) or CF may help explain the sometimes lower levels of active SLPI found in these patients (7).
Although originally identified as an antiprotease, more recent data has shed light on alternative functions of SLPI. In particular, SLPI has been shown to exhibit antiinflammatory/immune-modulatory functions that are not directly related to its anti-protease role.
Indeed the protein has been found to antagonise TNF, lipopolysaccharide (LPS)-and oxidized lowdensity lipoprotein (oxLDL)-induced activation of NFκB, a major mediator of innate immune responses (11, 12) . SLPI exerts its effects on NFκB signalling in a number of ways. By inhibiting the interaction between CD14 and LPS, SLPI interferes with the uptake of the latter (13) . Exogenously applied SLPI has been shown, at least in peripheral blood monocytes, to be taken into the cell and distributed around both the cytoplasm and the nucleus. In monocytes, SLPI can block NFκB activation by inhibiting the degradation of IκBα and IκBβ, inhibitors of NFκB (14) . Interestingly, binding of DNA by SLPI has been demonstrated, and in particular, SLPI has been shown to compete with the NFκB subunit p65 for binding to sites in the promoter regions of NFκB-regulated genes (15) .
This ultimately results in the down-regulation of production pro-inflammatory cytokines.
Recombinant SLPI, when administered in an aerosol form to CF patients, can not only suppress airway NE levels but can also reduce interleukin (IL)-8 levels in bronchoalveolar lavage fluid obtained from these patients (16) .
In addition to its antiprotease and immune-modulatory functions, SLPI also demonstrates antimicrobial activity in vitro. It has antimicrobial activity against many human pathogens including bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus (17) , fungi such as Candida albicans (18) , and even HIV (19) . Although the molecular mechanisms by which this antimicrobial activity is mediated are not yet well understood, it is believed that the highly cationic nature of the protein may be involved in the disruption of the cell membrane. It is also postulated that the antiprotease function of SLPI may aid in this antimicrobial effect through targeting pathogen-derived proteases (20) .
Regulation of SLPI expression
SLPI is expressed constitutively at various mucosal surfaces however several factors including cytokines and steroid hormones can regulate its inducible expression. The SLPI promoter contains a lung specific element responsible for fine tuning its expression in lung epithelium (21) . In these cells SLPI expression can be increased by LPS, IL-1, TNF, NE and neutrophil -defensins (22) (23) (24) (25) (26) . Corticosteriods can also induce SLPI expression in epithelial cells (27) whilst in skin and endometrium epidermal growth factor receptor (EGFR) signalling plays a role in its regulation (28, 29) . In macrophages SLPI is also increased in response to LPS but surprisingly not IL-1 or TNF, instead the cytokines IL-6 and IL-10 can enhance SLPI in these cells, albeit with slower kinetics that LPS (30) . In vitro TGF decreases SLPI expression in bronchial epithelial cells (31) .
Post transcriptional and epigenetic regulation of SLPI are topics that are less well explored.
IL-1-induced expression of SLPI in airway epithelial cells appears to involve histone H3-K4 trimethylation across the SLPI coding region, an effect that can be inhibited by the methylase inhibitor 5-azacytidine (32) . However whether other epigenetic mechanisms such as histone deactylation or microRNA repression regulate SLPI has not been shown but is no doubt currently under investigation. Dysregulation of miRNA has been found to occur in many human diseases including those of the lung. These include but are not limited to cancers, COPD, CF and asthma. For example, miR-126 has been shown to be downregulated in the bronchial epithelium of patients with CF (39). The fact that this miRNA has been shown to have an involvement in allergic asthma, angiogenesis, breast cancer and other malignancies highlights the multifaceted roles of miRNA in health and disease (35) .
To date there have been no studies examining whether miRNAs that regulate SLPI are altered in vivo in individuals with genetic or environmental inflammatory lung diseases.
SLPI, inflammatory lung disease and female gender
SLPI appears to play an important part in the progression of certain inflammatory lung diseases. For example, SLPI concentrations are higher in lung secretions of patients with chronic bronchitis, a disease characterised by infection and neutrophilic inflammation, as opposed to healthy controls. Results from studies with these patients suggest an inverse correlation exists between SLPI levels and the risk of developing an exacerbation (40) . Interestingly, our group has recently shown that 17β-estradiol (E2), the primary estrogen in non-pregnant females, is capable of abrogating Toll-like Receptor (TLR) responsiveness by upregulating SLPI in CF bronchial epithelial cells (Figure 2 ). This in turn inhibits the secretion of the neutrophil chemokine IL-8, by inhibiting NFκB signalling via mechanisms described earlier (41) . One may wonder how this anti-inflammatory effect of E2 could have negative consequences in the chronically inflamed airways of CF patients.
The current paradigm proposes that during acute exacerbations, surges in inflammation may be protective and that E2/SLPI-mediated inhibition of inflammation, coupled with E2's effect on decreasing airway surface liquid height in CF females (42) , is overall disadvantageous to CF females.
This role of E2 helps explain the clinical observations that females with CF have increased mortality and tend to have more aggressive disease than their male counterparts (43) .
Recent studies have shown that patients with allergic asthma express substantially higher levels of SLPI compared to healthy controls, and that SLPI may have a role in protecting the airways from asthma-induced inflammation (Figure 2 ) (44, 45) . Expression of SLPI actually protects against allergic asthma in a mouse ovalbumin model of asthma, and this may be related to the earlier observations that SLPI can blocking tryptase-induced bronchoconstriction and hyperresponsiveness (46) . E2 may have a role in asthma severity as it has been observed that exacerbations are less common in females at times of high circulating E2 (mid-menstrual cycle) when SLPI expression should be highest and more common in times of low E2 (menstruation). Decreased exacerbation rates and improved pulmonary function have been observed in some female asthma sufferers while undergoing hormone-replacement therapy and in those taking oral contraceptives (47) .
Hormonal regulation of SLPI is not a new concept (48, 49) . Estrogen increases SLPI expression in both rat and human uterine epithelium (50, 51) , and in post-menopausal women its expression is significantly decreased compared to peri-menopausal women or post-menopausal women treated with hormone replacement (52) . Tissue-specific expression of SLPI has also been linked to progesterone, with SLPI expression lowest in endometrium and highest in breast epithelium at times of low and high circulating progersterone, respectively (49, 53) . Interestingly intrauterine expression of SLPI is decreased in women with recurring lower reproductive tract infections (54) . The observation that hormonal regulation of SLPI by E2 occurs in tissues other than those in the reproductive tract and breast, expands its potential role as a gender-specific factor in a variety of diseases.
It is widely accepted that E2 plays a complex role in inflammatory processes and can exerts both pro-and anti-inflammatory effects. These differences are due in part to the differential tissue expression of the two main forms of its receptor (Estrogen Receptor, ER), namely ERα and ERβ. For example, E2 acts through ERβ in the CF bronchial epithelium (41). This is likely to be different in monocytic cells where ERα predominates over ERβ. It is also possible that E2 mediates important changes in post-transcriptional regulation of SLPI via miRNA.
Conclusions
With respect to gender dichotomies in lung disease, relatively little is known about the molecular mechanisms involved. It is almost certain that microRNAs play some role in mediating these gender differences in inflammatory lung diseases, but to date these remain largely unexplored. Unravelling these mechanisms will lead to a better understanding, and may open up new avenues for therapy of these diseases.
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